Allogeneic CAR-T cell therapy is produced using CRISPR gene editing from cells donated by healthy individuals.

TURKU, FI / ACCESS Newswire / May 30, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Phase I study shows promising clinical activity and tolerability of bexmarilimab plus standard-of-care in ...

Making CAR T Vision a reality will require the coming together of a complex ecosystem of partners, each with their own unique role to play. To learn more about CAR T Vision, review the roadmap report ...

CAR T cell immunotherapy, which uses a patient's own modified immune cells to find and destroy cancer cells, can produce ...

In the two decades since a young father was diagnosed with multiple myeloma, clinical trials and advances in treating his ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Autolus Therapeutics' autologous CD19-directed CAR T-cell therapy Aucatzyl ...

Don't dismiss persistent fatigue and bruising. These 11 warning signs could indicate acute myelogenous leukemia hiding in ...

Learn about acute myelogenous leukemia (AML), its sneaky symptoms, aggressive nature, and how bone marrow produces defective ...

Medically reviewed by Archana Sharma, DO Acute myelogenous leukemia (AML), also known as acute myeloid leukemia, is a type of ...

Located at the system's hospital in St. George, Utah, the clinic intends to offer T-cell collection closer to home.

An international study has uncovered why a widely used treatment for acute myeloid leukemia (AML) doesn't work for everyone. The findings could help doctors better match patients with the therapies ...